Drug-induced obesity
ICD-10 E66.1 is a billable code used to indicate a diagnosis of drug-induced obesity.
Drug-induced obesity is a condition characterized by excessive body weight resulting from the use of certain medications. This form of obesity can arise from various drug classes, including antidepressants, antipsychotics, corticosteroids, and certain anticonvulsants. The mechanism often involves alterations in metabolism, appetite stimulation, or changes in fat distribution. Patients may experience significant weight gain, which can lead to a body mass index (BMI) of 30 or higher. Clinicians must assess the patient's medication history and consider the potential for weight gain when prescribing these drugs. Management strategies may include lifestyle modifications, dietary changes, and, in some cases, pharmacotherapy aimed at weight reduction. It is essential to monitor patients for obesity-related complications such as type 2 diabetes, hypertension, and cardiovascular diseases, which can significantly impact their overall health and quality of life.
Complete medication history, BMI measurements, and documentation of weight management strategies.
Patients presenting with weight gain after starting new medications, routine obesity screenings.
Consideration of the patient's overall health and comorbidities when managing drug-induced obesity.
Detailed records of prescribed psychotropic medications and their side effects.
Patients on antipsychotics experiencing significant weight gain.
Balancing mental health treatment with the management of obesity.
Used during visits for weight management and counseling on obesity.
Document the counseling provided and the patient's weight status.
Primary care providers should ensure comprehensive documentation of lifestyle changes discussed.
Common medications include certain antidepressants (like mirtazapine), antipsychotics (such as olanzapine), corticosteroids, and some anticonvulsants. It's important to review the patient's medication list to identify potential causes.
